Section Arrow
PLRZ.NASDAQ
- Polyrizon Ltd
(Financial Status)
Quotes are at least 15-min delayed:2025/07/25 13:46 EDT
Regular Hours
Last
 1.5003
+0.1103 (+7.94%)
Day High 
1.59 
Prev. Close
1.39 
1-M High
2.45 
Volume 
2.58M 
Bid
1.5
Ask
1.51
Day Low
1.31 
Open
1.35 
1-M Low
0.66 
Market Cap 
7.41M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.11 
20-SMA 0.91 
50-SMA 1.12 
52-W High 1,200 
52-W Low 0.55 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-125.00/--
Enterprise Value
7.41M
Balance Sheet
Book Value Per Share
0.99
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.0558+0.0018+3.33%-- 
ABPAbpro Holdings Inc0.3179+0.0518+19.47%-- 
TNFATNF Pharmaceuticals Inc.0.1163-0.0157-11.89%-- 
PHIOPhio Pharmaceuticals Corp3.18+0.67+26.69%0.01PE
ABSIAbsci Corp2.91-0.6-17.09%-- 
Quotes are at least 15-min delayed:2025/07/25 13:46 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.